Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tandem Diabetes Care ( (TNDM) ) has provided an update.
At its May 20, 2026 annual meeting, Tandem Diabetes Care stockholders approved amendments to the company’s certificate of incorporation to permit removal of directors with or without cause under Delaware law and to extend liability protections for officers, with the updated charter filed in Delaware on May 21, 2026. Shareholders also backed an increase of 3,260,000 shares under the 2023 Long-Term Incentive Plan, re-elected nine directors, approved executive compensation, and ratified Ernst & Young LLP as auditor, signaling strong investor support for the board’s governance, compensation, and capital allocation framework.
These governance changes align the company more closely with current Delaware corporate law while bolstering officer protections, potentially aiding leadership retention amid a competitive medtech landscape. The expanded equity pool under the incentive plan enhances Tandem’s ability to attract and retain key talent, while the solid voting margins across proposals underscore investor confidence in the company’s strategic direction and oversight.
The most recent analyst rating on (TNDM) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.
Spark’s Take on TNDM Stock
According to Spark, TipRanks’ AI Analyst, TNDM is a Neutral.
The score is held back primarily by weak financial quality (ongoing losses, slightly negative free cash flow, and materially higher leverage with reduced equity) and a strongly bearish technical setup (below key moving averages with negative MACD). These are partially offset by a constructive earnings call with reaffirmed 2026 guidance, record operational performance, and improving margins.
To see Spark’s full report on TNDM stock, click here.
More about Tandem Diabetes Care
Tandem Diabetes Care, Inc. operates in the medical device industry, focusing on advanced technology solutions for people with diabetes. The company develops and commercializes insulin delivery systems, including insulin pumps and related diabetes management tools, targeting patients requiring intensive insulin therapy and competing in the broader diabetes care and digital health markets.
Average Trading Volume: 2,353,347
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.03B
For an in-depth examination of TNDM stock, go to TipRanks’ Overview page.